Destination XL Group (DXLG) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
3 Jun, 2026Executive summary
Net sales for Q1 fiscal 2026 were $103.3 million, down 2.1% year-over-year, with comparable sales down 3.8%—the best quarterly comp since Q2 2023.
Net loss was $5.9 million ($0.11 per diluted share), compared to $1.9 million ($0.04 per share) last year.
Adjusted net loss was $0.06 per share, versus $0.04 last year; adjusted EBITDA was a loss of $0.7 million, compared to a $0.2 million gain.
Strategic initiatives included rollout of FITMAP® technology, AI-driven ecommerce enhancements, and adapting to changing customer needs due to GLP-1 medications.
The Board is reevaluating the FullBeauty Brands merger due to market conditions and counterparty leverage.
Financial highlights
Gross margin for Q1 was 44.3%, down from 45.1% last year, mainly due to tariffs, higher shipping costs, and increased markdowns.
SG&A expenses were 45% of sales, down $0.9 million year-over-year, mainly due to lower payroll and incentive costs, offset by higher marketing spend.
Adjusted EBITDA margin was (0.7)% versus 0.2% last year.
Free cash flow for the first three months was a use of $12.7 million, improved from $18.8 million used last year.
Cash and investments were $16.2 million at quarter-end, with no debt and $70 million in credit facility availability.
Outlook and guidance
Marketing costs for fiscal 2026 expected to be 5.8% of sales.
Capital expenditures for fiscal 2026 projected at $8–$12 million, focused on technology, store projects, conversions, and relocations.
Tariffs expected to impact gross margin by 100 basis points if current rates persist, improved from prior 150 basis point estimate.
Comps for May were -5% to -6%, with expectations for similar trends in the second half of the year.
Cash and liquidity expected to be sufficient for at least the next 12 months.
Latest events from Destination XL Group
- Board now recommends voting against the FullBeauty merger issuance proposal due to risk concerns.DXLG
Proxy filing - Board recommends voting against the FullBeauty merger due to debt and dilution concerns.DXLG
Proxy filing - DXL's Board reverses support for merger, citing dilution and risk, and urges a vote against share issuance.DXLG
Proxy filing - Sales and margins declined in 2025, with a major merger expected to close in Q2 2026.DXLG
Q4 2026 - Sales declined and a merger with FullBeauty aims for $25M synergies and $1.2B sales.DXLG
Q3 2026 - Shareholders will vote on directors, executive pay, auditor ratification, and review ESG progress.DXLG
Proxy Filing - Sales and margins declined, but inventory and liquidity remained strong.DXLG
Q3 2025 - Q2 sales and profit dropped, leading to lower full-year guidance and tighter capital discipline.DXLG
Q2 2025 - Sales and earnings fell, but margins and cash flow stayed strong amid sector headwinds.DXLG
Q4 2025